AbbVie chief's $20M-plus pay—and company jet-setting—headed skyward in 2016

AbbVie CEO Richard Gonzalez saw his pay package grow in 2016 to almost $21 million, despite declines in his stock awards and options.

AbbVie’s Richard Gonzalez was already on the list of highest-paid biopharma CEOs when he scored $20.81 million in 2015 pay. And for 2016, that number went up even higher.

Gonzalez pocketed $20.97 million in 2016, with less than $12,000 of the increase from a bump-up in his base salary, which rose to $1.6 million.

Instead, the difference-makers were jumps in incentive pay—which went from just under $3 million to $3.6 million—and pension value, which vaulted to $3.2 million from $2.5 million.


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

The value of Gonzalez' perks also shot up, to $859,216 from $791,063. One big reason? Personal air travel, which for Gonzalez climbed over the half-million mark this year to $535,834. CFO Bill Chase, by contrast, cost AbbVie just $112 worth of flying for the year. Gonzalez got around on land, too, though, netting $19,362 in corporate care benefits compared with last year’s $17,303.

That’s not to say Gonzalez took home more in every compensation category. His stock awards shrunk to $9.3 million from $9.7 million, and the difference in his option awards—which slid to $2.4 million from $3.2 million—was even greater.

2016 was a tricky year for AbbVie in some regards, with hep C combo Viekira Pak falling hard on new competition from Merck and powerhouse Humira missing some quarterly estimates, raising concerns for the company’s future.

The real test will come over the next couple of years, though, as biosimilar versions of the $16 billion Humira hit the market. AbbVie has pledged to “vigorously defend” its IP on its prime source of revenue, but some industry watchers expect biosimilar copycats—including Amgen’s already-approved Amjevita—to pounce next year.